Tech Company Financing Transactions
Juventas Therapeutics Funding Round
On 7/17/2012, Juventas Therapeutics landed $22.2 million in Series B financing from Triathlon Medical Ventures, Early Stage Partners and Fletcher Spaght Ventures.
Transaction Overview
Company Name
Announced On
7/17/2012
Transaction Type
Venture Equity
Amount
$22,200,000
Round
Series B
Investors
Proceeds Purpose
The proceeds will fund completion of ongoing Phase II clinical trials investigating the use of JVS-100 in treating patients with chronic heart failure or critical limb ischemia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3615 Superior Ave. 4403B
Cleveland, OH 44114
USA
Cleveland, OH 44114
USA
Phone
Website
Email Address
Overview
Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life--threatening diseases. The company's lead product, Stromal--cell Derived Factor 1 (SDF--1), has been shown to protect and repair tissue following organ--damage in a broad range of pre--clinical disease models.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Aras
Chief Medical Officer
Matthew Pollman
VP - Operations
Michael Fitzgerald
VP - Product Management
Joseph Pastore
Browse more venture capital transactions:
Prev: 7/17/2012: Totsy venture capital transaction
Next: 7/17/2012: Zadara venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs